BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ellingson BM, Bendszus M, Sorensen AG, Pope WB. Emerging techniques and technologies in brain tumor imaging. Neuro Oncol 2014;16 Suppl 7:vii12-23. [PMID: 25313234 DOI: 10.1093/neuonc/nou221] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Conte GM, Castellano A, Altabella L, Iadanza A, Cadioli M, Falini A, Anzalone N. Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software. Radiol Med 2017;122:294-302. [PMID: 28070841 DOI: 10.1007/s11547-016-0720-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
2 Schwarz D, Niederle T, Münch P, Hielscher T, Hassel JC, Schlemmer HP, Platten M, Winkler F, Wick W, Heiland S, Delorme S, Bendszus M, Bäumer P, Breckwoldt MO. Susceptibility-weighted imaging in malignant melanoma brain metastasis. J Magn Reson Imaging 2019;50:1251-9. [PMID: 30793419 DOI: 10.1002/jmri.26692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Marner L, Henriksen OM, Lundemann M, Larsen VA, Law I. Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective. Clin Transl Imaging 2017;5:135-49. [PMID: 28936429 DOI: 10.1007/s40336-016-0213-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
4 Molina D, Pérez-Beteta J, Luque B, Arregui E, Calvo M, Borrás JM, López C, Martino J, Velasquez C, Asenjo B, Benavides M, Herruzo I, Martínez-González A, Pérez-Romasanta L, Arana E, Pérez-García VM. Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival. Br J Radiol 2016;89:20160242. [PMID: 27319577 DOI: 10.1259/bjr.20160242] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
5 Pérez-Beteta J, Molina-García D, Martínez-González A, Henares-Molina A, Amo-Salas M, Luque B, Arregui E, Calvo M, Borrás JM, Martino J, Velásquez C, Meléndez-Asensio B, de Lope ÁR, Moreno R, Barcia JA, Asenjo B, Benavides M, Herruzo I, Lara PC, Cabrera R, Albillo D, Navarro M, Pérez-Romasanta LA, Revert A, Arana E, Pérez-García VM. Morphological MRI-based features provide pretreatment survival prediction in glioblastoma. Eur Radiol 2019;29:1968-77. [PMID: 30324390 DOI: 10.1007/s00330-018-5758-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
6 Rausch I, Zitterl A, Berroterán-Infante N, Rischka L, Prayer D, Fenchel M, Sareshgi RA, Haug AR, Hacker M, Beyer T, Traub-Weidinger T. Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods. Eur Radiol 2019;29:4276-85. [PMID: 30635757 DOI: 10.1007/s00330-018-5942-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pérez-beteta J, Molina-garcía D, Ortiz-alhambra JA, Fernández-romero A, Luque B, Arregui E, Calvo M, Borrás JM, Meléndez B, Rodríguez de Lope Á, Moreno de la Presa R, Iglesias Bayo L, Barcia JA, Martino J, Velásquez C, Asenjo B, Benavides M, Herruzo I, Revert A, Arana E, Pérez-garcía VM. Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma. Radiology 2018;288:218-25. [DOI: 10.1148/radiol.2018171051] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 7.5] [Reference Citation Analysis]
8 Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015;17:1188-98. [PMID: 26250565 DOI: 10.1093/neuonc/nov095] [Cited by in Crossref: 77] [Cited by in F6Publishing: 158] [Article Influence: 11.0] [Reference Citation Analysis]
9 Kamiya-Matsuoka C, Gilbert MR. Treating recurrent glioblastoma: an update. CNS Oncol 2015;4:91-104. [PMID: 25768333 DOI: 10.2217/cns.14.55] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
10 Brandes AA, Finocchiaro G, Zagonel V, Reni M, Fabi A, Caserta C, Tosoni A, Eoli M, Lombardi G, Clavarezza M, Paccapelo A, Bartolini S, Cirillo L, Agati R, Franceschi E. Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. Oncotarget 2017;8:55575-81. [PMID: 28903444 DOI: 10.18632/oncotarget.15735] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
11 Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol 2017;1:20. [PMID: 29202103 DOI: 10.1038/s41698-017-0020-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Vellmer S, Edelhoff D, Suter D, Maximov II. Anisotropic diffusion phantoms based on microcapillaries. Journal of Magnetic Resonance 2017;279:1-10. [DOI: 10.1016/j.jmr.2017.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Dodo T, Okada T, Yamamoto A, Kanagaki M, Fushimi Y, Okada T, Sakata A, Arakawa Y, Miyamoto S, Togashi K. T1-weighted MR imaging of glioma at 3T: a comparative study of 3D MPRAGE vs. conventional 2D spin-echo imaging. Clin Imaging 2016;40:1257-61. [PMID: 27639863 DOI: 10.1016/j.clinimag.2016.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Pham TM, Sikdar KC, Cheung WY, Roa W, Eckstrand A, Kaposhi B, Shack L. Premature Mortality Due to Malignancies of the Central Nervous System in Canada, 1980-2010. Neuroepidemiology 2018;50:195-200. [PMID: 29694962 DOI: 10.1159/000488145] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Packer RA, Rossmeisl JH, Kent MS, Griffin JF 4th, Mazcko C, LeBlanc AK. Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials. Vet Radiol Ultrasound 2018;59:261-71. [PMID: 29522650 DOI: 10.1111/vru.12608] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
16 Conte GM, Altabella L, Castellano A, Cuccarini V, Bizzi A, Grimaldi M, Costa A, Caulo M, Falini A, Anzalone N. Comparison of T1 mapping and fixed T1 method for dynamic contrast-enhanced MRI perfusion in brain gliomas. Eur Radiol 2019;29:3467-79. [PMID: 30972545 DOI: 10.1007/s00330-019-06122-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
17 Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol. 2017;35:2439-2449. [PMID: 28640707 DOI: 10.1200/jco.2017.72.7511] [Cited by in Crossref: 123] [Cited by in F6Publishing: 69] [Article Influence: 24.6] [Reference Citation Analysis]
18 Ellingson BM, Kim GHJ, Brown M, Lee J, Salamon N, Steelman L, Hassan I, Pandya SS, Chun S, Linetsky M, Yoo B, Wen PY, Mellinghoff IK, Goldin J, Cloughesy TF. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib. Neuro Oncol 2021:noab256. [PMID: 34751786 DOI: 10.1093/neuonc/noab256] [Reference Citation Analysis]
19 Pathak R, Ragheb H, Thacker NA, Morris DM, Amiri H, Kuijer J, deSouza NM, Heerschap A, Jackson A. A data-driven statistical model that estimates measurement uncertainty improves interpretation of ADC reproducibility: a multi-site study of liver metastases. Sci Rep 2017;7:14084. [PMID: 29075009 DOI: 10.1038/s41598-017-14625-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
20 Warntjes M, Blystad I, Tisell A, Larsson EM. Synthesizing a Contrast-Enhancement Map in Patients with High-Grade Gliomas Based on a Postcontrast MR Imaging Quantification Only. AJNR Am J Neuroradiol 2018;39:2194-9. [PMID: 30409854 DOI: 10.3174/ajnr.A5870] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Le Fèvre C, Lhermitte B, Ahle G, Chambrelant I, Cebula H, Antoni D, Keller A, Schott R, Thiery A, Constans JM, Noël G. Pseudoprogression versus true progression in glioblastoma patients: A multiapproach literature review: Part 1 - Molecular, morphological and clinical features. Crit Rev Oncol Hematol 2021;157:103188. [PMID: 33307200 DOI: 10.1016/j.critrevonc.2020.103188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Molina-García D, Vera-Ramírez L, Pérez-Beteta J, Arana E, Pérez-García VM. Prognostic models based on imaging findings in glioblastoma: Human versus Machine. Sci Rep 2019;9:5982. [PMID: 30979965 DOI: 10.1038/s41598-019-42326-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
23 Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 2018;9:1474. [PMID: 29662077 DOI: 10.1038/s41467-018-03905-6] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 16.0] [Reference Citation Analysis]
24 Lindner T, Debus H, Fiehler J. Virtual non-contrast enhanced magnetic resonance imaging (VNC-MRI). Magn Reson Imaging 2021;81:67-74. [PMID: 34119648 DOI: 10.1016/j.mri.2021.06.004] [Reference Citation Analysis]
25 Goryawala M, Roy B, Gupta RK, Maudsley AA. T1-weighted and T2-weighted Subtraction MR Images for Glioma Visualization and Grading. J Neuroimaging 2021;31:124-31. [PMID: 33253433 DOI: 10.1111/jon.12800] [Reference Citation Analysis]
26 Hashido T, Saito S, Ishida T. Radiomics-Based Machine Learning Classification for Glioma Grading Using Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging. J Comput Assist Tomogr 2021;45:606-13. [PMID: 34270479 DOI: 10.1097/RCT.0000000000001180] [Reference Citation Analysis]